Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D04QBY
|
|||
Drug Name |
PMID29649907-Compound-27
|
|||
Drug Type |
Small molecular drug
|
|||
Company |
SALK INSTITUTE FOR BIOLOGICAL STUDIE
|
|||
Structure |
Download2D MOL |
|||
Formula |
C32H35FN2O3
|
|||
Canonical SMILES |
CN(C)C1=CC=C(C=C1)C2=CC(=C(C=C2)CN(C3=CC=CC(=C3)C=CC(=O)OC)C(=O)C4CCCCC4)F
|
|||
InChI |
1S/C32H35FN2O3/c1-34(2)28-17-15-24(16-18-28)26-13-14-27(30(33)21-26)22-35(32(37)25-9-5-4-6-10-25)29-11-7-8-23(20-29)12-19-31(36)38-3/h7-8,11-21,25H,4-6,9-10,22H2,1-3H3/b19-12+/i22D
|
|||
InChIKey |
BRNNEWSVEXDLGK-OFSGRHOTSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Farnesoid X-activated receptor (FXR) | Target Info | Agonist | [1] |
Target's Patent Info | Farnesoid X-activated receptor (FXR) | Target's Patent Info | [1] | |
KEGG Pathway | Bile secretion | |||
Pathway Interaction Database | RXR and RAR heterodimerization with other nuclear receptor | |||
Reactome | Recycling of bile acids and salts | |||
PPARA activates gene expression | ||||
Endogenous sterols | ||||
WikiPathways | Nuclear Receptors in Lipid Metabolism and Toxicity | |||
Nuclear Receptors Meta-Pathway | ||||
Farnesoid X Receptor Pathway | ||||
Drug Induction of Bile Acid Pathway |
References | Top | |||
---|---|---|---|---|
REF 1 | Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.